Ovid Therapeutics Inc. (OVID)
NASDAQ: OVID · Real-Time Price · USD
2.740
-0.190 (-6.48%)
Aug 20, 2026, 4:00 PM EDT - Market closed
Ovid Therapeutics Stock Forecast
Stock Price Forecast
According to 10 analysts polled by S&P Global, Ovid Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $5.69. The average 1-year stock price forecast is 107.66% higher than the current stock price, while the lowest is $4.00 (+45.99%) and the highest is $9.00 (+228.47%).
Price Target: $5.69 (+107.66%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Ovid Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '26 | Mar '26 | Apr '26 | May '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 10 | 10 | 10 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| LifeSci Capital | LifeSci Capital | Buy Reiterates $5 | Buy | Reiterates | $5 | +82.48% | Aug 14, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $9 | Buy | Reiterates | $9 | +228.47% | Aug 14, 2026 |
| Wedbush | Wedbush | Buy Maintains $7 | Buy | Maintains | $7 | +155.47% | Aug 14, 2026 |
| William Blair | William Blair | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 13, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 13, 2026 |
Financial Forecast
Revenue This Year
840.62K
from 7.25M
Decreased by -88.41%
Revenue Next Year
223.30K
from 840.62K
Decreased by -73.44%
EPS This Year
-0.38
from -0.23
EPS Next Year
-0.39
from -0.38
EPS and Forward PE are based on non-GAAP adjusted numbers.